ProfileGDS5678 / 1423731_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 77% 73% 77% 77% 81% 80% 78% 78% 76% 77% 77% 78% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3014278
GSM967853U87-EV human glioblastoma xenograft - Control 25.264877
GSM967854U87-EV human glioblastoma xenograft - Control 34.7703673
GSM967855U87-EV human glioblastoma xenograft - Control 45.3587477
GSM967856U87-EV human glioblastoma xenograft - Control 55.2303977
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6521881
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4605480
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3447878
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.446778
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1768776
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2487977
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2834677
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4240378
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4317779